Iambic closed an oversubscribed financing that brought in over $100 million to advance its AI‑discovered therapeutics and platform technologies, with participation from strategic life‑science investors including ARK and Regeneron. The company plans to accelerate multiple discovery programs and pursue additional partnerships and clinical starts. The raise follows growing investor interest in AI‑driven biotech; Iambic has also been active on dealmaking, including collaboration with Jazz and Revolution Medicines. The financing strengthens the company’s runway for early clinical expansion and validates investor appetite for platform‑first biotech models.